Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Part of paid clinical trials in Tampa, Florida.

Sponsor
Fox Chase Cancer Center
Study ID
NCT01059552
Phase
PHASE1
Status
Completed

Conditions

  • Locally Advanced Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • vorinostat — DRUG
    vorinostat once daily for 12 weeks of therapy

Study Details

The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.

Key Dates

Start date
Dec 16, 2009
Status verified
Nov 2019
Primary completion
Jul 22, 2015
Completion
Oct 21, 2019

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: vorinostat
    Dose escalation of vorinostat, cisplatin, pemetrexed and radiation

Primary Outcome Measure

To assess that safety and maximally tolerated dose of vorinostat in combination with chemoradiation for unresectable locally advanced NSCLC. [ Time Frame: toxicity assessments will occur weekly ]

Locations (3)

FacilityCityStateZIPSite coordinators
Moffitt Cancer CenterTampaFlorida33612-
Fox Chase Cancer CenterPhiladelphiaPennsylvania19111-
Medical University of South CarolinaCharlestonSouth Carolina29425-

Find similar trials in Tampa, FL

By research site
Moffitt Cancer Center· Tampa, FLFox Chase Cancer Center· Philadelphia, PAMedical University of South Carolina· Charleston, SC